Lyell Immunopharma, Inc. (LYEL)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
7.43 USD
-0.09
(-1.132%) ⇩
(Oct. 14, 2026, 12:49 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:59 a.m. EDT
The investment case here is structurally broken. The company is hemorrhaging cash with operating losses exceeding $130 million and free cash flow of -$73 million, all while revenue has collapsed by half year-over-year. The balance sheet is deteriorating rapidly, with debt-to-equity nearly 20x and a massive hole in shareholder equity. Fundamentally, this is a value trap; the market has correctly priced the business as failing, evidenced by four consecutive years of double-digit declines and a cumulative loss of over 93% since the last major anchor point. While the stock trades below book value, the negative return on equity and lack of profitability mean there is no margin of safety. On the short end, the technicals are bearish with the price trading well below moving averages, and options flow confirms a heavy hedge against further drops. There is no catalyst visible to reverse this multi-year decline, making this a dangerous hold for any timeframe. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.123530 |
| AutoARIMA | 0.123556 |
| AutoETS | 0.128341 |
| MSTL | 0.128341 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 2.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.154 |
| Excess Kurtosis | -1.03 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 19.929 |
| Revenue per Share | 0.001 |
| Market Cap | 181,950,672 |
| Forward P/E | -1.17 |
| Beta | -0.03 |
| Website | https://www.lyell.com |
As of Oct. 10, 2026, 2:59 a.m. EDT: Speculators are aggressively positioning for downside protection with heavy put volume and open interest at strikes significantly above the current price (e.g., 11.0, 13.0, 14.0), while call activity is sparse and concentrated near the money. The implied volatility surface shows elevated premiums for out-of-the-money puts relative to calls, indicating a market consensus focused on risk mitigation rather than speculative upside.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5678941 |
| Address1 | 201 Haskins Way |
| Address2 | Suite 101 |
| All Time High | 396.8 |
| All Time Low | 7.39 |
| Ask | 9.45 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 140,870 |
| Average Daily Volume3 Month | 145,287 |
| Average Volume | 145,287 |
| Average Volume10Days | 140,870 |
| Beta | -0.032 |
| Bid | 5.46 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 9.993 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.425 |
| Current Ratio | 5.356 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 7.75 |
| Day Low | 7.32 |
| Debt To Equity | 19.929 |
| Display Name | Lyell Immunopharma |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,793,995,200 |
| Earnings Timestamp Start | 1,793,995,200 |
| Ebitda | -180,944,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.147 |
| Enterprise To Revenue | 982.578 |
| Enterprise Value | 26,529,608 |
| Eps Current Year | -6.92 |
| Eps Forward | -6.32 |
| Eps Trailing Twelve Months | -12.86 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.3001 |
| Fifty Day Average Change | -4.8751 |
| Fifty Day Average Change Percent | -0.39634636 |
| Fifty Two Week Change Percent | -56.78941 |
| Fifty Two Week High | 45.0 |
| Fifty Two Week High Change | -37.575 |
| Fifty Two Week High Change Percent | -0.83500004 |
| Fifty Two Week Low | 7.32 |
| Fifty Two Week Low Change | 0.10500002 |
| Fifty Two Week Low Change Percent | 0.014344265 |
| Fifty Two Week Range | 7.32 - 45.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,623,936,600,000 |
| Float Shares | 12,133,966 |
| Forward Eps | -6.32 |
| Forward P E | -1.1748418 |
| Free Cashflow | -72,809,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 161 |
| Fullday Change | -0.08500004 |
| Fullday Change Percent | -1.1318247 |
| Fullday Price | 7.425 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.0 |
| Gross Profits | 27,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.37307 |
| Held Percent Institutions | 0.54221 |
| Implied Shares Outstanding | 24,505,141 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-17 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,748,822,400 |
| Last Split Factor | 1:20 |
| Long Business Summary | Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. |
| Long Name | Lyell Immunopharma, Inc. |
| Market | us_market |
| Market Cap | 181,950,672 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_590661061 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -248,476,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 258,774,288 |
| Number Of Analyst Opinions | 8 |
| Open | 7.42 |
| Operating Cashflow | -133,260,000 |
| Operating Margins | -11,834.25 |
| Overall Risk | 8 |
| Phone | 650 695 0677 |
| Previous Close | 7.51 |
| Price Eps Current Year | -1.072977 |
| Price Hint | 2 |
| Price To Book | 0.7430201 |
| Price To Sales Trailing12 Months | 6,738.9136 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.12 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.08500004 |
| Regular Market Change Percent | -1.1318247 |
| Regular Market Day High | 7.75 |
| Regular Market Day Low | 7.32 |
| Regular Market Day Range | 7.32 - 7.75 |
| Regular Market Open | 7.42 |
| Regular Market Previous Close | 7.51 |
| Regular Market Price | 7.425 |
| Regular Market Time | 1,791,996,541 |
| Regular Market Volume | 103,883 |
| Return On Assets | -0.34177 |
| Return On Equity | -0.93283 |
| Revenue Growth | -0.5 |
| Revenue Per Share | 0.001 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 24,505,141 |
| Shares Percent Shares Out | 0.051599998 |
| Shares Short | 1,263,394 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,131,628 |
| Short Name | Lyell Immunopharma, Inc. |
| Short Percent Of Float | 0.0602 |
| Short Ratio | 9.4 |
| Source Interval | 15 |
| State | CA |
| Symbol | LYEL |
| Target High Price | 49.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 37.875 |
| Target Median Price | 41.5 |
| Total Cash | 204,102,000 |
| Total Cash Per Share | 8.329 |
| Total Debt | 46,598,000 |
| Total Revenue | 27,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -12.86 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 18.055374 |
| Two Hundred Day Average Change | -10.630374 |
| Two Hundred Day Average Change Percent | -0.5887651 |
| Type Disp | Equity |
| Volume | 103,883 |
| Website | https://www.lyell.com |
| Zip | 94,080 |